489 related articles for article (PubMed ID: 28739772)
1. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
Jin F; Zhu H; Shi F; Kong L; Yu J
Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
4. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
6. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S
Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982
[TBL] [Abstract][Full Text] [Related]
7. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
12. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
13. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K
Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
16. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF
Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
[TBL] [Abstract][Full Text] [Related]
18. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled clinical study of
Wu Y; Feng J; Hu W; Luo Q
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28356484
[TBL] [Abstract][Full Text] [Related]
20. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
